China’s biotech market is staging a comeback that US biotech can only wish for
China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains in a rut. Buoyed by licensing deals, improving company fundamentals and regional support, Hong Kong’s Hang Seng ...
China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains in a rut.
Buoyed by licensing deals, improving company fundamentals and regional support, Hong Kong’s Hang Seng ...
